MONJUVI (tafasitamab-cxix)

OFFICE ADMINISTRATION - INTRAVENOUS (IV)

Indications for Prior Authorization:
  • MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Patients must meet the following criteria:

Diffuse large B-cell lymphoma (DLBCL):

  • Diagnosis of relapsed or refractory; AND
  • Prescribed by or in collaboration with an oncologist; AND
  • Used in combination with lenalidomide (Revlimid) for first 12 cycles; AND
  • Patient is not eligible for autologous stem cell transplant (ASCT).
This Medication Is Not Approvable for the Following Condition(s):

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics Committee.

Dosing:

The recommended dosage of MONJUVI is 12 mg/kg as an IV infusion according to the following dosing schedule (adults):

  • Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. 
  • Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. 
  • Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.

Administer MONJUVI in combination with lenalidomide for a maximum of 12 cycles and then continue MONJUVI as monotherapy until disease progression or unacceptable toxicity.

Approval:
  • Initial: 1 year.
  • Reauthorization: 1 year when documented that patient does not show evidence of progressive disease while on therapy.
Additional Information:
  • It is unclear if Monjuvi will have a negative impact on the efficacy of subsequent anti-CD19 CAR T-cell therapy.
Review History:
  • 02/16/2021- New policy.
References:
  • Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019-5032.
  • ClinicalTrials.gov Web site. https://clinicaltrials.gov/ct2/home. Identifiers: NCT04134936, NCT02763319, NCT02639910. Accessed September 10, 2020. 
  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808. Blood. 2018;131(5):587-588.
  • Food and Drug Administration. Multi-discipline review: Monjuvi. 2019. FDA Web site. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761163Orig1s000MultidisciplineR.pdf. Accessed September 8, 2020.
  • Food and Drug Administration. Press Release: FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. July 31, 2020. FDA Web site. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma. Accessed September 8, 2020. 
  • Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018;29(5):1266-1272.
  • Monjuvi [package insert], Boston, MA: Morphosys US, Inc.; July 2020.
  • National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology – B-Cell Lymphomas, version 4.2020 – August 13, 2020. NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed September 8, 2020.
  • Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
  • Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21(7):978-988.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. doi: 10.1182/blood-2016-01-643569.

Last review date: February 16, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone